Loading...

Rigel Pharmaceuticals

DB:RI2A
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RI2A
DB
$393M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
RI2A Share Price and Events
7 Day Returns
-4.4%
DB:RI2A
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-31.5%
DB:RI2A
-7.4%
DE Biotechs
-5.6%
DE Market
RI2A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rigel Pharmaceuticals (RI2A) -4.4% -3.5% 18.8% -31.5% -18.8% -8.2%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • RI2A underperformed the Biotechs industry which returned -7.4% over the past year.
  • RI2A underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
RI2A
Industry
5yr Volatility vs Market
Related Companies

RI2A Value

 Is Rigel Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Rigel Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €2.055.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rigel Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rigel Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RI2A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.44
NasdaqGS:RIGL Share Price ** NasdaqGS (2019-04-24) in USD $2.35
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rigel Pharmaceuticals.

DB:RI2A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RIGL Share Price ÷ EPS (both in USD)

= 2.35 ÷ -0.44

-5.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rigel Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Rigel Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Rigel Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:RI2A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
57.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rigel Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rigel Pharmaceuticals's assets?
Raw Data
DB:RI2A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.66
NasdaqGS:RIGL Share Price * NasdaqGS (2019-04-24) in USD $2.35
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:RI2A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RIGL Share Price ÷ Book Value per Share (both in USD)

= 2.35 ÷ 0.66

3.58x

* Primary Listing of Rigel Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rigel Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Rigel Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Rigel Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RI2A Future Performance

 How is Rigel Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rigel Pharmaceuticals expected to grow at an attractive rate?
  • Rigel Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Rigel Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Rigel Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RI2A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RI2A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 57.4%
DB:RI2A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 34.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RI2A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RI2A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 309 130 3
2022-12-31 252 83 3
2021-12-31 168 6 3
2020-12-31 83 -61 -68 5
2019-12-31 66 -72 -74 6
DB:RI2A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 45 -59 -70
2018-09-30 7 -90 -100
2018-06-30 3 -88 -93
2018-03-31 1 -80 -87
2017-12-31 4 -78 -78
2017-09-30 7 -70 -68
2017-06-30 10 -75 -73
2017-03-31 19 -74 -67
2016-12-31 20 -76 -69
2016-09-30 26 -77 -66
2016-06-30 35 -64 -50
2016-03-31 32 -64 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Rigel Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Rigel Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RI2A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Rigel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RI2A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.71 0.88 0.59 3.00
2022-12-31 0.46 0.55 0.36 3.00
2021-12-31 0.03 0.09 -0.01 3.00
2020-12-31 -0.37 -0.32 -0.44 5.00
2019-12-31 -0.43 -0.32 -0.57 6.00
DB:RI2A Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.44
2018-09-30 -0.64
2018-06-30 -0.65
2018-03-31 -0.65
2017-12-31 -0.62
2017-09-30 -0.59
2017-06-30 -0.68
2017-03-31 -0.67
2016-12-31 -0.73
2016-09-30 -0.72
2016-06-30 -0.56
2016-03-31 -0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rigel Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Rigel Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rigel Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RI2A Past Performance

  How has Rigel Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rigel Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rigel Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Rigel Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rigel Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Rigel Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rigel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RI2A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 44.51 -70.48 70.00
2018-09-30 6.65 -99.58 63.29
2018-06-30 2.69 -93.47 53.16
2018-03-31 0.90 -87.06 43.91
2017-12-31 4.48 -77.99 37.83
2017-09-30 7.48 -67.71 30.33
2017-06-30 10.34 -72.68 26.94
2017-03-31 18.94 -67.07 23.90
2016-12-31 20.38 -69.22 20.91
2016-09-30 25.92 -66.31 18.48
2016-06-30 35.16 -50.36 18.19
2016-03-31 31.75 -50.74 17.52
2015-12-31 28.90 -51.46 17.81
2015-09-30 28.61 -61.05 19.80
2015-06-30 15.61 -75.32 20.41
2015-03-31 10.43 -86.80 21.70
2014-12-31 8.25 -90.91 22.50
2014-09-30 5.75 -85.50 20.45
2014-06-30 5.75 -88.38 20.23
2014-03-31 7.15 -85.76 19.73
2013-12-31 7.15 -89.03 19.61
2013-09-30 1.40 -97.64 20.82
2013-06-30 1.40 -99.27 13.12
2013-03-31 1.50 -101.24 17.99
2012-12-31 2.25 -98.84 22.85
2012-09-30 2.25 -99.16 27.39
2012-06-30 6.61 -91.63 39.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rigel Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rigel Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rigel Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rigel Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rigel Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RI2A Health

 How is Rigel Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rigel Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rigel Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rigel Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rigel Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Rigel Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rigel Pharmaceuticals Company Filings, last reported 3 months ago.

DB:RI2A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 109.88 0.00 128.54
2018-09-30 103.47 0.00 115.64
2018-06-30 123.57 0.00 134.99
2018-03-31 79.81 0.00 94.30
2017-12-31 100.65 0.00 115.75
2017-09-30 56.17 0.00 68.08
2017-06-30 69.61 0.00 82.30
2017-03-31 84.08 0.00 98.14
2016-12-31 55.03 0.00 74.77
2016-09-30 65.94 0.00 85.26
2016-06-30 73.72 0.00 94.94
2016-03-31 75.45 0.00 103.63
2015-12-31 91.38 0.00 126.28
2015-09-30 96.41 0.00 134.35
2015-06-30 101.15 0.00 143.94
2015-03-31 112.15 0.00 161.16
2014-12-31 128.25 0.00 143.16
2014-09-30 146.85 0.00 157.67
2014-06-30 165.73 0.00 176.03
2014-03-31 188.33 0.00 195.38
2013-12-31 208.25 0.00 211.98
2013-09-30 223.40 0.00 230.88
2013-06-30 245.05 0.00 251.64
2013-03-31 265.31 0.00 272.45
2012-12-31 289.10 0.00 298.24
2012-09-30 174.80 0.00 183.90
2012-06-30 195.75 0.00 202.64
  • Rigel Pharmaceuticals has no debt.
  • Rigel Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rigel Pharmaceuticals has sufficient cash runway for 2.1 years based on current free cash flow.
  • Rigel Pharmaceuticals has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 13.8% each year.
X
Financial health checks
We assess Rigel Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rigel Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RI2A Dividends

 What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rigel Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Rigel Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rigel Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rigel Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RI2A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RI2A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rigel Pharmaceuticals has not reported any payouts.
  • Unable to verify if Rigel Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rigel Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rigel Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Rigel Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Rigel Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rigel Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rigel Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RI2A Management

 What is the CEO of Rigel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Saad Waraich
COMPENSATION $2,172,790
TENURE AS CEO 4.4 years
CEO Bio

Mr. Saad Muzaffar Waraich has been the Chief Technology & Information Officer at Pakistan Telecommunication Company Limited since April 2016.

CEO Compensation
  • Saad's compensation has been consistent with company performance over the past year.
  • Saad's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Rigel Pharmaceuticals management team in years:

2.5
Average Tenure
56
Average Age
  • The tenure for the Rigel Pharmaceuticals management team is about average.
Management Team

Saad Waraich

TITLE
President
COMPENSATION
$2M
TENURE
4.4 yrs

Dolly Vance

TITLE
Executive VP of Corporate Affairs
COMPENSATION
$1M
AGE
53
TENURE
16.3 yrs

Anne-Marie Duliege

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$1M
AGE
59
TENURE
3.1 yrs

Eldon Mayer

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$712K
AGE
57
TENURE
2.5 yrs

Tom Raffin

TITLE
Co-Founder
AGE
71

Dean Schorno

TITLE
Executive VP & CFO
AGE
55
TENURE
0.9 yrs

Nelson Cabatuan

TITLE
VP of Finance & Interim Principal Accounting Officer
TENURE
1.3 yrs

Gio Matthews

TITLE
Executive Director of Market Access
TENURE
1.7 yrs

Stacy Markel

TITLE
Executive Vice President of Human Resources
AGE
53
TENURE
1.1 yrs

Esteban Masuda

TITLE
Senior Vice President of Research
AGE
56
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the Rigel Pharmaceuticals board of directors in years:

4.1
Average Tenure
63
Average Age
  • The tenure for the Rigel Pharmaceuticals board of directors is about average.
Board of Directors

Gary Lyons

TITLE
Chairman of the Board
COMPENSATION
$174K
AGE
67
TENURE
4.4 yrs

Saad Waraich

TITLE
President
COMPENSATION
$2M
TENURE
4.4 yrs

Walter Moos

TITLE
Director and Member of Scientific & Clinical Trial Advisory Committee
COMPENSATION
$140K
AGE
63
TENURE
22.1 yrs

Brad Goodwin

TITLE
Director
COMPENSATION
$142K
AGE
63
TENURE
12.3 yrs

Gregg Lapointe

TITLE
Director
COMPENSATION
$207K
AGE
59
TENURE
1.4 yrs

Peter Ringrose

TITLE
Director and Scientific & Clinical Trial Advisory Committee
COMPENSATION
$135K
AGE
72
TENURE
3.7 yrs

Keith Katkin

TITLE
Director
COMPENSATION
$135K
AGE
47
TENURE
3.8 yrs

Brian Kotzin

TITLE
Director and Member of Scientific & Clinical Trial Advisory Committee
COMPENSATION
$147K
AGE
69
TENURE
1.7 yrs

Jane Wasman

TITLE
Director
AGE
62
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Sep 18 Buy Eldon Mayer Individual 10. Sep 18 11. Sep 18 100,000 €2.83 €280,917
27. Aug 18 Buy Eldon Mayer Individual 23. Aug 18 23. Aug 18 100,000 €2.44 €243,924
21. Aug 18 Buy Saad Waraich Individual 17. Aug 18 17. Aug 18 114,000 €2.31 €262,862
X
Management checks
We assess Rigel Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rigel Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RI2A News

Simply Wall St News

RI2A Company Info

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company’s clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.

Details
Name: Rigel Pharmaceuticals, Inc.
RI2A
Exchange: DB
Founded: 1996
$351,030,110
167,179,088
Website: http://www.rigel.com
Address: Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RIGL Common Stock Nasdaq Global Select US USD 29. Nov 2000
DB RI2A Common Stock Deutsche Boerse AG DE EUR 29. Nov 2000
Number of employees
Current staff
Staff numbers
158
Rigel Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:53
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/03
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.